Stoke Therapeutics (STOK) Earnings Analysis

Stoke Therapeutics (STOK) has no confirmed upcoming earnings date. Last quarter (2026-05-07) it beat with EPS -0.79 USD vs -0.8 USD est (+1.3%). It has beaten estimates in 2/3 recent quarters (67%). Trailing P/E -10.23.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does STOK next report earnings?

No confirmed upcoming earnings date is currently scheduled for STOK. This page updates as the calendar is published.

STOK earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-07-0.79 USD-0.8 USD+1.3%Beat
2026-03-16-0.97 USD-0.75 USD-29.3%Miss
2025-03-18-0.18 USD-0.51 USD+64.7%Beat

Beat rate: 2/3 (67%) over reported quarters with consensus data.

STOK valuation and analyst view

Trailing P/E-10.23
Trailing EPS-2.692 USD
Price / book4.63
Dividend yield0.00%
Market cap1.74B
Analyst consensusBuy (12 buy / 3 hold / 0 sell)
Avg price target44 USD

Related research pages

Frequently asked questions

When is Stoke Therapeutics (STOK)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for STOK. This page updates as the calendar is published.

Did STOK beat earnings last quarter?

In its 2026-05-07 report, STOK posted EPS of -0.79 USD versus a -0.8 USD estimate — a beat of 1.3%.

What is STOK's earnings track record?

Over the last 3 reported quarters with consensus data, STOK beat estimates 2 times (67%).

What is STOK's current P/E ratio and EPS?

STOK trades at a trailing P/E of -10.23 on trailing EPS of -2.692000620897915 USD.

What do analysts rate STOK?

Analyst consensus is "Buy" across 15 ratings (0 strong buy, 12 buy, 3 hold, 0 sell, 0 strong sell). Average 12-month price target: 44 USD.